Navigation Links
10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide
Date:1/8/2008

ROCHESTER HILLS, Mich., Jan. 8 /PRNewswire/ -- CSG/SportsCoatings, today announced approximately 10 million square feet of synthetic turf will be treated with its industry-leading antimicrobial coating, TurfAide(TM), in 2008 -- up from 1.5 million square feet in 2007.

The exponential increase in demand for TurfAide has been attributed to several factors, including a 2007 report in the Journal of the American Medical Association that found MRSA (methicillin-resistant Staphlycoccus aureas) is responsible for more than 94,000 serious infections and nearly 19,000 deaths each year. MRSA, a potentially deadly skin infection, is caused by staph bacteria that can survive on surfaces for days. The antimicrobial technology in TurfAide is proven to inhibit the growth of bacteria, fungi and mold for years with just one application.

According to three studies conducted by the Texas Department of State Health Services, the MRSA infection rate among football players is 16 times higher than the average person. Texas has synthetic turf at 18 percent of its high school fields.

"Schools, professional teams and recreation centers are recognizing the growing threat of sports-related infections," said CSG/SportsCoatings CEO Craig Andrews. "More synthetic turf systems will be treated with TurfAide than all other antimicrobial products combined in 2008; because it's a proven and powerful technology that's been safely used in medical and consumer goods for over 30 years."

"With bacterial infections like MRSA and fungi like ringworm affecting many student athletes across the country, the need to protect your facilities has become a necessity," said Jim Weaver, Virginia Tech University Athletics Director.

Virginia Tech University is one of many major Division I programs, National Football League franchises and high schools that have had their synthetic turf fields treated with TurfAide in the past 18 months. A small sampling of TurfAide clients includ
'/>"/>

SOURCE CSG/SportsCoatings
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Romark Laboratories Raises $18 Million in Institutional Financing
2. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
3. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
4. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
5. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
6. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
7. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
8. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
9. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
10. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...-FirstCall/--CardioGenicsHoldingsInc.(OTCBulletinB...ingtheimmunoassaysegmentoftheIVDtestingmarket,repo...ngtothenextphaseofthecommercializationofCardioGeni..."). ,, PertheagreementwithMerckChimiethatwasexe...iewithitsproprietarysilvercoatedparamagneticbeadsf...
(Date:11/24/2009)...--NeurocrineBiosciences,Inc.(Nasdaq: NBIX )announc...fficerofNeurocrineBiosciences,willbepresentingatth...rk. ,, ThelivepresentationtakesplaceTuesday,Dec...icTime(PT).Thepresentationwillbesimultaneouslywebc...www.neurocrine.com . ,, Ifyouareunabletoattendt...
(Date:11/24/2009)...stCall/--IsisPharmaceuticals,Inc.(Nasdaq: ISIS ),t...managementwillpresentacompanyoverviewatPiperJaffra...r1,2009,at10:30a.m.ETatTheNewYorkPalaceHotel. ,...eonthe"Investors&Media"sectionoftheCompany,sWe...willbeavailableontheIsisWebsitewithin48hoursandwil...
Breaking Medicine Technology:CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3FSU researcher wins 242 4M in grants to pursue early detection of autism 59560 1FSU researcher wins 242 4M in grants to pursue early detection of autism 59560 2FSU researcher wins 242 4M in grants to pursue early detection of autism 59560 3Smoking Bans Good for Non Smokers Hearts 3A Study 59559 1Smoking Bans Good for Non Smokers Hearts 3A Study 59559 2Smoking Bans Good for Non Smokers Hearts 3A Study 59559 3Smoking Bans Reduce Heart Attacks 3A Study 59555 1Smoking Bans Reduce Heart Attacks 3A Study 59555 2Smoking Bans Reduce Heart Attacks 3A Study 59555 3
...ion pyridopyrazine-urea derivative compound series... be valuable for,cancer treatment, QUEBEC, April 1...Inc. , a global, pure play biopharmaceutical compa...y presented an abstract,outlining first in vitro d...lectivity for PI3K inhibition, at the American,Ass...
...ay Provide Cancer Patients With Improved Potential...16, 2007 /PRNewswire/ -- Insert,Therapeutics, Inc....h Corporation announced today its novel delivery s...oster presentation at,the 2007 American Associatio...rticular, this poster includes new research findin...
Other Medicine Technology:AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 2Poster on Cyclosert Drug Delivery Presented at AACR Meeting 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 4
(Date:11/24/2009)....24/PRNewswire/--Whiletheholidayseasonoftenbringsf...yearcanbedifficultforthosegrievingthedeathofaloved...andfamilies.Theholidayseasoncanbringadditionalchal...ngPlace,ACenterforGrievingChildren,AdolescentsandT...dditiontohavingavarietyofprintandonlineresourcesav...
(Date:11/24/2009)....,Nov.24/PRNewswire-FirstCall/--HealthSouthCorpora...heBankofAmericaMerrillLynch2009CreditConferenceinN...residentandTreasurerEdFaywillbespeakingonThursday,...stliveandwillbeavailableat http://investor.healths...HealthSouth ,, HealthSouthisthenation,slargest...
(Date:11/24/2009)...s didn,t differ greatly between high- and low-volu.... 24 (HealthDay News) -- Do hospitals that conduct...st results for patients? Maybe not. , Prior res...when it comes to artery-opening procedures, but a ...- and high-volume hospitals performing more or les...
(Date:11/24/2009)...a,Nov.24/PRNewswire-FirstCall/-HardtoTreatDiseases...gsubsidiarySlavicaBioChem,isprovidingthisbriefupda...inuesduediligencewiththeEUstemcellcompanyandmerger...oraboutOct29,2009whichthecompanymade. http://www.p...News . ,, HTDSandSlavicaBiochemarealsodiscussin...
(Date:11/24/2009)...24/PRNewswire/--Metastorm,aleadingproviderofBusine...PA),andEnterpriseArchitecture(EA)softwareforaligni...merisourceBergenCorporation,oneoftheworld,slargest...rdforNorthAmericainthe2009GlobalAwardsforExcellenc...implementationofMetastorm,sBPMsoftware.Theawardrec...
Breaking Medicine News(10 mins):Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 2Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 3Health News:Metastorm Customer Wins Global Excellence in BPM & Workflow Award 2
...arch 5 AmericInn(R) International, LLC officially...,s new sleep advocacy and awareness campaign, with.... The new Web portal is designed to educate consum...ter America" Web site centralizes unique sleep-rel...
... 3, 2009) - How messages sent within stem cells th... the cells to specialize and become blood cells in...McMaster Stem Cell and Cancer Research Institute. ...way, known as the noncanonical Wnt, in inducing bl...
...lternative Reproductive Resources (ARR) today ann...economic realities given the investment required f... Alternatives ," it offers incentive pricing to in...ome egg donors," said Robin von Halle, president o...
...cabbage block protein in disease spread, study say...- A drug based on compounds extracted from crucife... offer a potent and safe treatment against melanom...production and blocked the signaling network of a ...
... and Asia to Realize New Executive Leadership , ,...okyo Stock Exchange), a leading medical diagnosti...ion systems developer, today announced executive l... Sysmex Corporate after a six-year tenure in the U...
...clinical trial involving more than 3,000 women in ...first time the promise of a vaginal microbicide ge... to findings presented at the Conference on Retrov...30% effective. While the results are encouraging, ...
Other Medicine News:Health News:AmericInn Hotels Kicks-Off 'Sleep Better America' With Launch of New Web Site to Educate Consumers About Insomnia and Sleep-Related Issues 2Health News:Drugs From Vegetables May Target Melanoma Tumors 2Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Clinical trial finds microbicide promising as HIV prevention method for women 2
Graftech Cervical Spacer
Neuroclip Cranial Flap Fixation System
Timesh 1.6
Craniofix Titanium Clamp
Medicine Products: